Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this retrospective analysis, the authors reported that off-label tofacitinib treatment in 35 alopecia areata patients demonstrated safety, with no serious adverse events, and effectiveness, with 83.9% showing significant scalp regrowth and 32.3% achieving near total or total regrowth.

This study found that tofacitinib was a safe and effective treatment for patients with moderate-to-severe alopecia areata, with a significant percentage achieving notable reductions in their Severity of Alopecia Tool scores after 18 months.

This review discusses conventional and alternative treatments for trigeminal autonomic cephalalgias, including cluster headache, paroxysmal hemicrania, and SUNCT, and recommends specific medications without reporting new clinical findings.

In this study, oral tofacitinib was associated with significant hair regrowth in patients with alopecia areata, achieving over 50% reduction in Severity of Alopecia Tool scores, with mild side effects.

In this study, tazarotene 0.1% gel showed greater efficacy than tretinoin 0.025% gel in reducing acne lesions and demonstrated similar efficacy to adapalene 0.1% gel when used less frequently.

This case report highlights a rare association between congenital triangular alopecia and vitiligo, noting that treatment with tofacitinib improved the patient's vitiligo but not the alopecia.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

This study compared oral tofacitinib and methotrexate in treating moderate-to-severe alopecia areata, finding that tofacitinib was more effective at reducing SALT scores and improving scalp hair assessment PRO scores, though both treatments reduced psychological distress similarly without serious adverse effects.

In this study, retrospective analysis of patients with severe alopecia areata showed that oral JAK inhibitors, tofacitinib and baricitinib, reduced hair loss significantly, with comparable effectiveness; longer tofacitinib use was linked to greater improvement, while baricitinib achieved substantial outcomes quickly.

This review highlights the potential of Sacituzumab Tirumotecan, an antibody-drug conjugate, in treating gynecologic cancers, with ongoing Phase III trials indicating a manageable safety profile and future results expected to shed light on its effectiveness in improving survival and response rates.

In this case report, a young female Indian patient with alopecia areata saw hair regrowth within 2 months of treatment with oral tofacitinib, with continued improvements over a 5-month period and no reported side effects.

In this study, tofacitinib showed significant efficacy in treating alopecia totalis and universalis over a 6-month period, with notable hair regrowth outcomes, while younger age of onset and shorter treatment duration were linked to less effectiveness.

Tofacitinib may effectively treat folliculitis decalvans.

This study found that tofacitinib effectively promoted hair regrowth in Asian patients with severe alopecia areata, with 74.3% showing a clinical response.

This study found that overexpression of the transcription factor Tcf3 accelerates keratinocyte migration and skin wound healing in mice, highlighting its potential as a therapeutic target for wound repair.

This article discusses temporal triangular alopecia, emphasizing the need for increased awareness to prevent misdiagnosis and ineffective treatment, but reports no new clinical results.

In this study, inactivating the TAF4 subunit of transcription factor TFIID in mouse epidermis disrupted gene expression linked to skin and hair function, and increased tumor risk.

This case report describes a 21-year-old woman with circumscribed alopecia areata incognita, who experienced a sustained positive response to treatment with oral tofacitinib after conventional treatments frequently failed to provide lasting effects.

This study describes the ongoing HABIT study in Taicang, China, which aims to identify risk factors and the relationship between cardiovascular and neurodegenerative diseases among 10,357 adults, by collecting and analyzing long-term data on health, lifestyle, and biological specimens. Results are not yet available.

This review provides a synopsis of 53 cases of temporal triangular alopecia, noting its frequent detection in early childhood and potential association with congenital diseases, but it reports no new clinical findings.

In this case report, a young adult male with resistant alopecia areata showed nearly 90% hair regrowth after 3 months of treatment with tofacitinib, alongside biotin supplementation, without any side effects observed.

The authors concluded that capecitabine and high-dose toremifene may be an effective treatment option for patients unable to undergo anthracycline or taxane therapies, based on one woman's cancer management.

In this research letter from the British Journal of Dermatology, the authors explore the use of topical tofacitinib to treat alopecia areata affecting facial hair, but specific results are not reported in the abstract.

In this quasi-experimental study, 24-week tofacitinib treatment significantly improved hair regrowth in South Asian patients with alopecia areata, but a high relapse rate post-withdrawal signals the need for continuous treatment strategies.

This study found that oral tofacitinib significantly reduced alopecia severity and improved quality of life over 12 months for children with moderate to severe alopecia areata, though the authors recommend more research due to the small sample size and absence of a control group.

Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.

This study in Mexican adolescents with severe alopecia areata reported that oral tofacitinib treatment resulted in hair growth and reduced alopecia severity without serious adverse effects.

In this open-label trial, Tofacitinib was well tolerated and improved IFN and cytokine scores, as well as overall skin pathology, in individuals with Down syndrome and immune skin conditions.

This study suggests that oral tofacitinib may be an effective treatment for beard regrowth in men with alopecia areata of the beard, with a strong correlation observed between beard and scalp hair regrowth.

In this retrospective study, tofacitinib showed promise as a treatment for alopecia areata, with 46.5% of patients experiencing a very good response and minimal adverse effects, suggesting it could be a primary option for moderate to severe cases.